Effects of Food on the Pharmacokinetics of Omega-3-Carboxylic Acids in Healthy Japanese Male Subjects: A Phase I, Randomized, Open-label, Three-period, Crossover Trial. 2017

Hitoshi Shimada, and Catarina Nilsson, and Yoshinori Noda, and Hyosung Kim, and Torbjörn Lundström, and Toshitaka Yajima
AstraZeneca KK.

OBJECTIVE Omega-3-carboxylic acids (OM3-CA) contain omega-3 free fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), as carboxylic acids. Food intake is known to affect the bioavailability of ethyl ester fatty acid formulations. We conducted a phase I study to investigate the effects of the timing of OM3-CA administration relative to food intake on the pharmacokinetics of EPA and DHA. METHODS In this randomized, open-label, three-period crossover study, Japanese healthy male subjects were administered 4×1 g OM3-CA capsules with continued fasting, before a meal, or after a meal. All subjects fasted for ≥10 h prior to drug/meal administration. The primary objective was to examine the effect of meal timing on the pharmacokinetics of EPA and DHA after OM3-CA administration. The secondary objectives were to examine the safety and tolerability of OM3-CA. RESULTS A total of 42 Japanese subjects was enrolled in the study. The baseline-adjusted maximum concentration and area under the concentration-time curve from 0 to 72 h for EPA, DHA, and EPA +DHA were lower in the fasting and before meal conditions than in the after meal condition. The maximum total EPA, total DHA, and total EPA+DHA concentrations were reached later when administered in fasting conditions than in fed conditions, indicating slower absorption in fasting conditions. Diarrhea was reported by five, six, and no subjects in the fasting, before meal, and after meal conditions, respectively. CONCLUSIONS The timing of OM3-CA administration relative to food intake influences the systemic bioavailability of EPA and DHA in healthy Japanese male subjects. BACKGROUND NCT02372344.

UI MeSH Term Description Entries
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002264 Carboxylic Acids Organic compounds containing the carboxy group (-COOH). This group of compounds includes amino acids and fatty acids. Carboxylic acids can be saturated, unsaturated, or aromatic. Carboxylic Acid,Acid, Carboxylic,Acids, Carboxylic
D004281 Docosahexaenoic Acids C22-unsaturated fatty acids found predominantly in FISH OILS. Docosahexaenoate,Docosahexaenoic Acid,Docosahexenoic Acids,Docosahexaenoic Acid (All-Z Isomer),Docosahexaenoic Acid Dimer (All-Z Isomer),Docosahexaenoic Acid, 3,6,9,12,15,18-Isomer,Docosahexaenoic Acid, 4,7,10,13,16,19-(All-Z-Isomer),Docosahexaenoic Acid, 4,7,10,13,16,19-(All-Z-Isomer), Cerium Salt,Docosahexaenoic Acid, 4,7,10,13,16,19-(All-Z-Isomer), Cesium Salt,Docosahexaenoic Acid, 4,7,10,13,16,19-(All-Z-Isomer), Potassium Salt,Docosahexaenoic Acid, 4,7,10,13,16,19-(Z,Z,Z,Z,Z,E-Isomer),Docosahexaenoic Acid, 4,7,10,13,16,19-Isomer,Docosahexaenoic Acid, 4,7,10,13,16,19-Isomer, Sodium Salt,Docosahexaenoic Acid, Sodium Salt,Acid, Docosahexaenoic,Acids, Docosahexaenoic,Acids, Docosahexenoic
D004435 Eating The consumption of edible substances. Dietary Intake,Feed Intake,Food Intake,Macronutrient Intake,Micronutrient Intake,Nutrient Intake,Nutritional Intake,Ingestion,Dietary Intakes,Feed Intakes,Intake, Dietary,Intake, Feed,Intake, Food,Intake, Macronutrient,Intake, Micronutrient,Intake, Nutrient,Intake, Nutritional,Macronutrient Intakes,Micronutrient Intakes,Nutrient Intakes,Nutritional Intakes
D005215 Fasting Abstaining from FOOD. Hunger Strike,Hunger Strikes,Strike, Hunger,Strikes, Hunger
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

Hitoshi Shimada, and Catarina Nilsson, and Yoshinori Noda, and Hyosung Kim, and Torbjörn Lundström, and Toshitaka Yajima
January 2023, Drug design, development and therapy,
Hitoshi Shimada, and Catarina Nilsson, and Yoshinori Noda, and Hyosung Kim, and Torbjörn Lundström, and Toshitaka Yajima
November 2020, Clinical pharmacology in drug development,
Hitoshi Shimada, and Catarina Nilsson, and Yoshinori Noda, and Hyosung Kim, and Torbjörn Lundström, and Toshitaka Yajima
January 2012, Clinical drug investigation,
Hitoshi Shimada, and Catarina Nilsson, and Yoshinori Noda, and Hyosung Kim, and Torbjörn Lundström, and Toshitaka Yajima
January 2012, Clinical drug investigation,
Hitoshi Shimada, and Catarina Nilsson, and Yoshinori Noda, and Hyosung Kim, and Torbjörn Lundström, and Toshitaka Yajima
September 2020, Clinical therapeutics,
Hitoshi Shimada, and Catarina Nilsson, and Yoshinori Noda, and Hyosung Kim, and Torbjörn Lundström, and Toshitaka Yajima
February 2019, Clinical therapeutics,
Hitoshi Shimada, and Catarina Nilsson, and Yoshinori Noda, and Hyosung Kim, and Torbjörn Lundström, and Toshitaka Yajima
October 2019, International journal of clinical pharmacology and therapeutics,
Hitoshi Shimada, and Catarina Nilsson, and Yoshinori Noda, and Hyosung Kim, and Torbjörn Lundström, and Toshitaka Yajima
January 2009, Clinical drug investigation,
Hitoshi Shimada, and Catarina Nilsson, and Yoshinori Noda, and Hyosung Kim, and Torbjörn Lundström, and Toshitaka Yajima
December 2004, Clinical therapeutics,
Hitoshi Shimada, and Catarina Nilsson, and Yoshinori Noda, and Hyosung Kim, and Torbjörn Lundström, and Toshitaka Yajima
July 2010, Clinical therapeutics,
Copied contents to your clipboard!